Alcon, Inc.

Alcon Laboratories, Inc.

Alcon Research, Ltd.

Alcon Manufacturing, Ltd.

Shire Orphan Therapies Gmbh

Other

Astellas Pharma Gmbh

Iok-Hou Pang

Mark R Hellberg

Abbot F Clark

Michael A Kapin

Allan R Shepard

Debra L Fleenor

Peter G Klimko

Najam A Sharif

Hwang-Hsing Chen

Louis DeSantis, Jr

Wan-Heng Wang

Loretta Graves McNatt

Keith D Combrink

Abdelmoula Namil

Bryon Severns

Peggy Elizabeth Hellberg

Nasreen Jacobson

Debra L Shade

Suchismita Mohapatra

Ganesh Prasanna

Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.

Methods of treating ophthalmic diseases using NPR-B agonists

NPR-B agonists

The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.

Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma

RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.

RNAi inhibition of CTGF for treatment of ocular disorders

Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection.

Use of inhibitors of Jun N-terminal kinases to treat glaucoma

Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.

Method of treating glaucoma

The use of inhibitors of GSK-3 useful for treating glaucoma is disclosed.

Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma

The invention provides pharmaceutical compositions containing non-feminizing estrogen and methods of using these compositions to prevent or ameliorate retinal vascular diseases.

Use of non-feminizing estrogens as treatment for retinal vascular diseases

The invention provides pharmaceutical compositions containing non-feminizing estrogen and methods of using these compositions to prevent or ameliorate retinal and optic nerve damage associated with glaucoma.

Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).

Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

Compositions comprising AP-1 activators and methods of use for treating glaucoma and ocular hypertension are disclosed.

Use of AP-1 activators to treat glaucoma and ocular hypertension

Compositions and methods for the treatment of retina and optic nerve head neuropathy are disclosed. The compositions and methods are particularly directed to the use of neurotrophic factor stimulators, such as AIT-082 (neotrofin), in the treatment of glaucomatous neuropathy.

Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases

The invention provides pharmaceutical compositions containing PARP inhibitors and methods of using these compositions to prevent, treat or ameliorate glaucomatous retinopathy and/or optic neuropathy.

Growing community of inventors

Grand Prairie, TX, United States of America

Iok-Hou Pang